196 related articles for article (PubMed ID: 33392713)
1. APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application.
Filbert EL; Björck PK; Srivastava MK; Bahjat FR; Yang X
Cancer Immunol Immunother; 2021 Jul; 70(7):1853-1865. PubMed ID: 33392713
[TBL] [Abstract][Full Text] [Related]
2. Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy.
Vitale LA; Thomas LJ; He LZ; O'Neill T; Widger J; Crocker A; Sundarapandiyan K; Storey JR; Forsberg EM; Weidlick J; Baronas AR; Gergel LE; Boyer JM; Sisson C; Goldstein J; Marsh HC; Keler T
Cancer Immunol Immunother; 2019 Feb; 68(2):233-245. PubMed ID: 30382327
[TBL] [Abstract][Full Text] [Related]
3. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
Richman LP; Vonderheide RH
Cancer Immunol Res; 2014 Jan; 2(1):19-26. PubMed ID: 24416732
[TBL] [Abstract][Full Text] [Related]
4. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
Carpenter EL; Mick R; Rüter J; Vonderheide RH
J Transl Med; 2009 Nov; 7():93. PubMed ID: 19906293
[TBL] [Abstract][Full Text] [Related]
5. Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.
Yu X; Chan HTC; Orr CM; Dadas O; Booth SG; Dahal LN; Penfold CA; O'Brien L; Mockridge CI; French RR; Duriez P; Douglas LR; Pearson AR; Cragg MS; Tews I; Glennie MJ; White AL
Cancer Cell; 2018 Apr; 33(4):664-675.e4. PubMed ID: 29576376
[TBL] [Abstract][Full Text] [Related]
6. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y
J Virol; 2017 May; 91(9):. PubMed ID: 28202751
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.
Li F; Ravetch JV
Science; 2011 Aug; 333(6045):1030-4. PubMed ID: 21852502
[TBL] [Abstract][Full Text] [Related]
8. Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity.
Ishihara J; Ishihara A; Potin L; Hosseinchi P; Fukunaga K; Damo M; Gajewski TF; Swartz MA; Hubbell JA
Mol Cancer Ther; 2018 Nov; 17(11):2399-2411. PubMed ID: 30097487
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses.
Jackaman C; Nelson DJ
Cancer Immunol Immunother; 2012 Apr; 61(4):549-60. PubMed ID: 22002241
[TBL] [Abstract][Full Text] [Related]
10. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity.
de Silva S; Fromm G; Shuptrine CW; Johannes K; Patel A; Yoo KJ; Huang K; Schreiber TH
Cancer Immunol Res; 2020 Feb; 8(2):230-245. PubMed ID: 31852716
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
Front Immunol; 2021; 12():786144. PubMed ID: 35095862
[TBL] [Abstract][Full Text] [Related]
12. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies.
Horton HM; Bernett MJ; Peipp M; Pong E; Karki S; Chu SY; Richards JO; Chen H; Repp R; Desjarlais JR; Zhukovsky EA
Blood; 2010 Oct; 116(16):3004-12. PubMed ID: 20616215
[TBL] [Abstract][Full Text] [Related]
13. Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity.
Yu X; Chan HTC; Fisher H; Penfold CA; Kim J; Inzhelevskaya T; Mockridge CI; French RR; Duriez PJ; Douglas LR; English V; Verbeek JS; White AL; Tews I; Glennie MJ; Cragg MS
Cancer Cell; 2020 Jun; 37(6):850-866.e7. PubMed ID: 32442402
[TBL] [Abstract][Full Text] [Related]
14. Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
White AL; Dou L; Chan HT; Field VL; Mockridge CI; Moss K; Williams EL; Booth SG; French RR; Potter EA; Butts C; Al-Shamkhani A; Cragg MS; Verbeek JS; Johnson PW; Glennie MJ; Beers SA
J Immunol; 2014 Aug; 193(4):1828-35. PubMed ID: 25024386
[TBL] [Abstract][Full Text] [Related]
15. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.
Wilson NS; Yang B; Yang A; Loeser S; Marsters S; Lawrence D; Li Y; Pitti R; Totpal K; Yee S; Ross S; Vernes JM; Lu Y; Adams C; Offringa R; Kelley B; Hymowitz S; Daniel D; Meng G; Ashkenazi A
Cancer Cell; 2011 Jan; 19(1):101-13. PubMed ID: 21251615
[TBL] [Abstract][Full Text] [Related]
16. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus.
He W; Tan GS; Mullarkey CE; Lee AJ; Lam MM; Krammer F; Henry C; Wilson PC; Ashkar AA; Palese P; Miller MS
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):11931-11936. PubMed ID: 27698132
[TBL] [Abstract][Full Text] [Related]
17. CD40-activated B cells contribute to mesothelioma tumor regression.
Jackaman C; Cornwall S; Graham PT; Nelson DJ
Immunol Cell Biol; 2011 Feb; 89(2):255-67. PubMed ID: 20628372
[TBL] [Abstract][Full Text] [Related]
18. Systemic immune response to a CD40 agonist antibody in nonhuman primates.
Caudell DL; Dugan GO; Babitzki G; Schubert C; Braendli-Baiocco A; Wasserman K; Acona G; Stern M; Passioukov A; Cline JM; Charo J
J Leukoc Biol; 2024 May; 115(6):1084-1093. PubMed ID: 38372596
[TBL] [Abstract][Full Text] [Related]
19. Agonistic CD40 antibodies and cancer therapy.
Vonderheide RH; Glennie MJ
Clin Cancer Res; 2013 Mar; 19(5):1035-43. PubMed ID: 23460534
[TBL] [Abstract][Full Text] [Related]
20. Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.
Kornbluth RS; Stempniak M; Stone GW
Int Rev Immunol; 2012 Aug; 31(4):279-88. PubMed ID: 22804572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]